SRPT241122P170000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Express News | Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS
Express News | Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board
Express News | Sarepta Therapeutics Inc - Approves $500 Million Share Repurchase Authorization
Express News | Sarepta Therapeutics Inc - Arrowhead to Receive $500 Million Upfront and $325 Million Equity Investment
Express News | Sarepta Therapeutics Inc - Obtains Exclusive Licenses to Seven Programs
Express News | Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement With Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical Sirna Programs
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Analyst Expectations For Sarepta Therapeutics's Future
Sarepta Therapeutics Analyst Ratings
H.C. Wainwright Initiates Sarepta Therapeutics(SRPT.US) With Sell Rating, Announces Target Price $80
Express News | Sarepta Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Sell Rating and Target Price $80
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $197
J.P. Morgan Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Express News | Sarepta Therapeutics Inc : JP Morgan Cuts Target Price to $197 From $202
S&P 500 Futures Climb In Premarket Trading; Target, Fabrinet Lag
Barclays Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $209
High Alpha Stocks That Are Rated 'Overweight' – MS
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $210
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200